192 related articles for article (PubMed ID: 15923311)
1. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit.
Grundmann S; Hoefer I; Ulusans S; van Royen N; Schirmer SH; Ozaki CK; Bode C; Piek JJ; Buschmann I
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1497-505. PubMed ID: 15923311
[TBL] [Abstract][Full Text] [Related]
2. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C
J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039
[TBL] [Abstract][Full Text] [Related]
3. Arteriogenesis proceeds via ICAM-1/Mac-1- mediated mechanisms.
Hoefer IE; van Royen N; Rectenwald JE; Deindl E; Hua J; Jost M; Grundmann S; Voskuil M; Ozaki CK; Piek JJ; Buschmann IR
Circ Res; 2004 May; 94(9):1179-85. PubMed ID: 15059933
[TBL] [Abstract][Full Text] [Related]
4. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
5. Chronic Elevation of Tumor Necrosis Factor-α Mediates the Impairment of Leptomeningeal Arteriogenesis in db/db Mice.
Yukami T; Yagita Y; Sugiyama Y; Oyama N; Watanabe A; Sasaki T; Sakaguchi M; Mochizuki H; Kitagawa K
Stroke; 2015 Jun; 46(6):1657-63. PubMed ID: 25922509
[TBL] [Abstract][Full Text] [Related]
6. [Inhibitors of TNFalpha].
Brousse C
Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
[TBL] [Abstract][Full Text] [Related]
7. Time course of arteriogenesis following femoral artery occlusion in the rabbit.
Hoefer IE; van Royen N; Buschmann IR; Piek JJ; Schaper W
Cardiovasc Res; 2001 Feb; 49(3):609-17. PubMed ID: 11166274
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy.
Coury F; Ferraro-Peyret C; Le Cam S; Guerin S; Tebib J; Sibilia J; Bienvenu J; Fabien N
Clin Exp Rheumatol; 2008; 26(2):234-9. PubMed ID: 18565243
[TBL] [Abstract][Full Text] [Related]
9. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
van den Brande J; Hommes DW; Peppelenbosch MP
J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
[TBL] [Abstract][Full Text] [Related]
10. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
Agnholt J; Dahlerup JF; Kaltoft K
Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
Shanahan JC; St Clair W
Clin Immunol; 2002 Jun; 103(3 Pt 1):231-42. PubMed ID: 12173297
[TBL] [Abstract][Full Text] [Related]
13. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
Bibbo C; Goldberg JW
Foot Ankle Int; 2004 May; 25(5):331-5. PubMed ID: 15134615
[TBL] [Abstract][Full Text] [Related]
14. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
15. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes.
Haider AS; Cardinale IR; Whynot JA; Krueger JG
J Investig Dermatol Symp Proc; 2007 May; 12(1):9-15. PubMed ID: 17502863
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF agents for rheumatoid arthritis.
Seymour HE; Worsley A; Smith JM; Thomas SH
Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis.
Hoefer IE; van Royen N; Rectenwald JE; Bray EJ; Abouhamze Z; Moldawer LL; Voskuil M; Piek JJ; Buschmann IR; Ozaki CK
Circulation; 2002 Apr; 105(14):1639-41. PubMed ID: 11940540
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis.
Schirmer SH; Buschmann IR; Jost MM; Hoefer IE; Grundmann S; Andert JP; Ulusans S; Bode C; Piek JJ; van Royen N
Cardiovasc Res; 2004 Nov; 64(2):356-64. PubMed ID: 15485696
[TBL] [Abstract][Full Text] [Related]
20. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
Mitoma H; Horiuchi T; Hatta N; Tsukamoto H; Harashima S; Kikuchi Y; Otsuka J; Okamura S; Fujita S; Harada M
Gastroenterology; 2005 Feb; 128(2):376-92. PubMed ID: 15685549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
